Mitsui sets up cancer JV in Singapore
Japan's Mitsui has established a 50:50 joint venture in Singapore withthe country's National Cancer Center, called Agenica Research. Mitsui is putting S$3.8 million ($2.1 million) into the JV over two years, and the funding will be used to develop a molecular gene expression database for breast cancer. Agenica will also be involved in research projects involving diseases "that are of interest and relevance to Asian populations."
NCC will conduct the necessary research, while Mitsui will market the completed database to pharmaceutical companies worldwide. The latter will also assist Agenica in inviting "mainly Japanese pharmaceutical and bio-device manufacturers" to its laboratories for training and joint research purposes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze